Supernus Pharmaceuticals (SUPN) Free Cash Flow (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Free Cash Flow data on file, last reported at $66.5 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 119.75% year-over-year to $66.5 million in Q1 2026; TTM through Mar 2026 was $82.2 million, a 49.65% decrease from a year earlier, with the FY2025 full-year figure at $46.0 million, down 73.14% from the prior year.
• Free Cash Flow for Q1 2026 stood at $66.5 million, up from $19.4 million in the prior quarter.
• Over the last five years, Free Cash Flow for SUPN reached as high as $71.1 million in Q2 2022 and fell as low as -$61.8 million in Q3 2025.
• Historically, Free Cash Flow has averaged $30.0 million across 5 years, with a median of $35.7 million in 2023.
• Across the five-year window, Free Cash Flow soared 1201.57% in 2023 and tumbled 215.89% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at $27.7 million in 2022, then surged by 62.25% to $45.0 million in 2023, then fell by 1.78% to $44.2 million in 2024, then plunged by 56.02% to $19.4 million in 2025, then soared by 242.31% to $66.5 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were $66.5 million in Q1 2026, $19.4 million in Q4 2025, and -$61.8 million in Q3 2025.